A Aralex Aachen research explorer

Doris Augustin Sign in to save

ORCID 0000-0002-5193-7528 OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

0

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (2)

3× Breast Center Ostbayern, Deggendorf, Germany
1× 12Breast Center Ostbayern, Deggendorf, Germany

Papers 4 stored

All · Aachen affiliation only

Data from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
2023 other Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access

0

citations
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
2022 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access

14

citations
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
2022 The Lancet Oncology article Medicine HER2/EGFR in Cancer Research

93

citations
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
2022 Annals of Oncology erratum Medicine HER2/EGFR in Cancer Research Open access

1

citations

4 results